149 related articles for article (PubMed ID: 36775105)
1. Ancillary tests for hepatobiliary neoplasms: what we know and what we need to know.
Zhang SL; Wang HL
Hum Pathol; 2023 Nov; 141():183-200. PubMed ID: 36775105
[TBL] [Abstract][Full Text] [Related]
2. [Combined hepatocellular-cholangiocarcinoma].
Jeen YM; Jin SY
Korean J Hepatol; 2007 Dec; 13(4):571-5. PubMed ID: 18159156
[No Abstract] [Full Text] [Related]
3. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
4. A Review on the Update of Combined Hepatocellular Cholangiocarcinoma.
Komuta M; Yeh MM
Semin Liver Dis; 2020 May; 40(2):124-130. PubMed ID: 31887773
[TBL] [Abstract][Full Text] [Related]
5. Utility and Limitations of Albumin mRNA In Situ Hybridization Detection in the Diagnosis of Hepatobiliary Lesions and Metastatic Carcinoma to the Liver.
Collins K; Newcomb PH; Cartun RW; Ligato S
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):180-187. PubMed ID: 33208670
[TBL] [Abstract][Full Text] [Related]
6. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
Tischoff I; Tannapfel A
Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
[TBL] [Abstract][Full Text] [Related]
7. [Synchronous double primary hepatic cancer: hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
Kim JO; Jun DW; Jang K
Korean J Gastroenterol; 2013 Aug; 62(2):135-9. PubMed ID: 24133714
[No Abstract] [Full Text] [Related]
8. How Molecular Discoveries Have Changed Liver Tumor Pathology: A Brief Review.
Taheri N; Graham RP
Arch Pathol Lab Med; 2024 May; 148(5):e96-e102. PubMed ID: 37639429
[TBL] [Abstract][Full Text] [Related]
9. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1/INI1 Is Diagnostically Useful in Distinguishing α-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Kondo T
Anticancer Res; 2018 Dec; 38(12):6865-6868. PubMed ID: 30504402
[TBL] [Abstract][Full Text] [Related]
11. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
12. Update on Ancillary Testing in the Evaluation of High-Grade Liver Tumors.
Koehne de Gonzalez A; Lagana SM
Surg Pathol Clin; 2018 Jun; 11(2):367-375. PubMed ID: 29751880
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
Sasaki M; Sato Y
Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
[TBL] [Abstract][Full Text] [Related]
14. [CT and MR imaging differences between intrahepatic cholangiocarcinoma and hepatocellular carcinoma with invasions to billary tracts].
Yang NJ; Song B; Wu B; Xu J; Zhao LM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):525-8. PubMed ID: 19627020
[TBL] [Abstract][Full Text] [Related]
15. [Combined hepatocellular carcinoma and cholangiocellular carcinoma].
Maeda Y; Nishida M; Mori N; Tamesa T; Okada T; Tangoku A; Oka M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():401-5. PubMed ID: 11761981
[No Abstract] [Full Text] [Related]
16. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
[TBL] [Abstract][Full Text] [Related]
17. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
[TBL] [Abstract][Full Text] [Related]
18. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
19. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
[TBL] [Abstract][Full Text] [Related]
20. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA; Taddei T; Jain D; Zhang X
Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
